

SHAROKY MELVIN MD
Form 4
September 07, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SHAROKY MELVIN MD

(Last) (First) (Middle)

10 FINDERNE AVENUE, BUILDING 10

(Street)

BRIDGEWATER, NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [INSM]

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock | 09/05/2017 | | S ⁽¹⁾ | | 8,466 | D | \$ 29 ⁽²⁾ |
| | | | | | | | 267,262 ⁽⁷⁾ |
| Common Stock | 09/05/2017 | | S ⁽¹⁾ | | 12,128 | D | \$ 28.69 ⁽³⁾ |
| | | | | | | | 255,134 |
| Common Stock | 09/05/2017 | | S ⁽¹⁾ | | 4,406 | D | \$ 29.35 ⁽⁴⁾ |
| | | | | | | | 250,728 |
| Common Stock | 09/06/2017 | | S ⁽¹⁾ | | 8,792 | D | \$ 26.07 ⁽⁵⁾ |
| | | | | | | | 241,936 |

Edgar Filing: SHAROKY MELVIN MD - Form 4

| | | | | | | | | | |
|--------|------------|--|------------------|--------|---|-----|-------|---------|---|
| Common | 09/06/2017 | | S ⁽¹⁾ | 16,208 | D | \$ | 25.71 | 225,728 | D |
| Stock | | | | | | (6) | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|-------|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|-------|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| SHAROKY MELVIN MD 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER, NJ 08807 | | X | | |

Signatures

/s/ Melvin Sharoky, by Christine Pellizzari as Attorney-in-fact 09/07/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- (2)

Edgar Filing: SHAROKY MELVIN MD - Form 4

The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$28.84 to \$29.20, inclusive.

- (3) The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$28.56 to \$28.82, inclusive.
- (4) The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$29.21 to \$29.50, inclusive.
- (5) The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$25.89 to \$26.40, inclusive.
- (6) The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$25.50 to \$25.88, inclusive.
- (7) The number of shares reflected here excludes 443 shares previously reported for which Dr. Sharoky does not have beneficial ownership.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.